COMPASS Pathways' COMP006 Part B Data Supports NDA Path, Execution Key

What happened

COMPASS Pathways presented six-month data from its second Phase 3 trial (COMP006 Part B) for COMP360 in treatment-resistant depression, reporting a rapid and durable profile that extends to 26 weeks. This reduces a key regulatory uncertainty, as management had framed Part B as the final dataset required for NDA completion. However, the company's own filings still tie NDA timing and commercialization to a complete application and FDA review, which now becomes the primary risk. The stock has already rallied on this data and is pricing in a smooth regulatory path, leaving limited upside unless the Q4 2026 NDA submission and CNPV expedited review proceed flawlessly. Investors should wait for either a pullback to the attractive entry or confirmation of a complete filing.

Implication

For investors, the COMP006 Part B data confirms the durability needed to support the NDA, shifting focus from clinical to regulatory execution. The market has already priced this outcome, with the stock trading near $13.60, so further upside requires a seamless Q4 2026 NDA submission and a compressed FDA review via the CNPV. Any delays, additional study requests, or manufacturing issues would likely trigger a sharp selloff. Given the crowded bullish narrative and the company's own warning that rolling review and CNPV may not guarantee speed, the risk/reward is balanced. We recommend maintaining a WAIT stance, with an attractive entry at $11 and a trim level at $17.50.

Thesis delta

The release of positive COMP006 Part B data resolves the near-term clinical risk, shifting the investment thesis from binary approval to execution on the regulatory timeline. The thesis now depends solely on the company's ability to complete the NDA in Q4 2026 and secure a favorable FDA review. Until that is proven, the defensive WAIT stance remains appropriate.